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Abstract
Growth factor stimulation induces Y783 phosphor-
ylation of phosphoinositide-specific PLC-γ1, and the 
subsequent activation of this enzyme in a cellular sig-
naling cascade. Previously, we showed that a double 
point mutation, Y509A/F510A, of PLC-γ1, abolished in-
teractions with translational elongation factor 1-α. 
Here, we report that the Y509A/F510A mutant PLC-γ1 
displayed extremely high levels of Y783 phosphor-
ylation and enhanced catalytic activity, compared to 
wild-type PLC-γ1, upon treatment of COS7 cells with 
EGF. In quiescent COS7 cells, the Y509A/F510A mutant 
PLC-γ1 exhibited a constitutive hydrolytic activity, 
whereas the wild-type counterpart displayed a basal 
level of activity. Upon treatment of COS7 cells with 
EGF, the Y783F mutation in Y509A/F510A PLC-γ1 
(Y509A/F510A/Y783F triple mutant) cells also led to an 
enhanced catalytic activity, whereas Y783F mutation 
alone displayed a basal level of activity. Our results col-
lectively suggest that the Y509A/F510A mutant is more 
susceptible to receptor tyrosine kinase-induced Y783 
phosphorylation than is wild-type PLC-γ1, but no lon-
ger requires Y783 phosphorylation step for the 
Y509A/F510A mutant PLC-γ1 activation in vivo.
Keywords: phosphatidylinositol 4,5-bisphosphate; 
phospholipase Cγ; protein-tyrosine kinases; src ho-
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Introduction
PLC-γ1 plays a pivotal role in cell growth and 
differentiation by hydrolyzing phosphatidylinositol 
4,5-bisphosphate (PIP2) to inositol 1,4,5-trisphos-
phate (IP3) and diacylglycerol (DG). Overexpre-
ssion of PLC-γ1 induces malignant transformation 
in nude mice (Chang et al., 1997) while targeted 
deletion of PLC-γ1 results in embryonic lethality in 
mice (Ji et al., 1997). The requirement for protein 
tyrosine phosphorylation prior to activation of 
PLC-γ1 is currently widely accepted (Kim et al., 
1991; Rhee, 2001; Poulin et al., 2005; Choi et al., 
2006). Briefly, agonist stimulation results in activa-
tion of receptor tyrosine kinases, such as the EGF 
receptor and the PDGF receptor, followed by asso-
ciation with PLC-γ1 (Rhee, 2001; Meisenhelder et 
al., 1989). This interaction allows receptor tyrosine 
kinases to phosphorylate PLC-γ1 at tyrosine 
residues, including Y771, Y783, and Y1254 (Kim et 
al., 1990, 1991; Wahl and Carpenter, 1998; Sekiya 
et al., 2004; Poulin et al., 2005). Among these 
residues, Y783 is proposed to be a critical phospho-
rylation site for enzyme activation, in view of the 
finding that the Y783F mutant protein is devoid of 
PIP2 hydrolyzing activity in agonist-treated cells 
(Kim et al., 1991; Sekiya et al., 2004; Poulin et al., 
2005).
    PLC-γ1 contains two PH domains for 
protein-protein and protein-lipid interaction. PH1 is 
located within the 150 residues closest to the 
N-terminus, whereas PH2 is located near the 
center of the molecule; the two domains are 
separated by the SH2-SH2-SH3 domain (Gibson et 
al., 1994; Kavran et al., 1998). PH domains bind 
with high specificity and affinity to PtdInsPs, such 
as PI(3)P, PI(4)P, PI(5)P, PI(3,4)P2, PI(3,5)P2, 
PI(4,5)P2, and PI(3,4,5)P3 (Runnels et al., 1996; 
Wang et al., 1999), and such domains in signaling 
molecules are often involved in targeted translo-
cation of molecules to cell membranes (Lemmon et 
al., 1996; Falasca et al., 1998). 
    A split PH2 domain (nPH2) is located immediately 
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Figure 1. Tyrosine phosphorylation of the Y509A/F510A mutant PLC-γ1. COS7 cells transfected with wild-type pFLAG-PLC-γ1 (WT) and 
pFLAG-Y509A/F510A mutant DNA were stimulated with 50 ng/ml EGF for 10 min, or were untreated. Lysates were immunoprecipitated with anti-FLAG 
M2 antibody. Immunoprecipitated proteins were resolved on 10% (w/v) SDS-PAGE, transferred to nitrocellulose membranes, and immunoblotted with an-
ti-phosphotyrosine (PY20) (A), anti-pY771 (B), anti-pY783 (C), or anti-pY1254 (D) antibodies, respectively (see above). Each membrane was reprobed 
with anti-FLAG antibody, to ensure normalization (see below). The diagrams under the immunoblots represent relative image intensities obtained from 
X-ray film analysis.
upstream of the N-terminal SH2 of PLC-γ1, and is 
involved in protein-protein interactions with EF-1α, 
β-tubulin, and NF-L (Chang et al., 2002, 2005; Kim 
et al., 2006). In a previous study, we demonstrated, 
for the first time, that the Y509 and F510 residues 
within the nPH2 domain were critical for pro-
tein-protein interaction, and a double point mutant 
(Y509A/F510A) completely lost binding affinity with 
EF-1α (Chang et al., 2002). Based on this finding, 
DeBell and colleagues (DeBell et al., 2007) further 
reported that a Y509A/F510A mutant protein 
modulated cellular calcium signaling and NF-AT 
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Figure 2. Comparison of IP3 production rates in COS7 cells transfected 
with wild-type and Y509A/F510A mutant PLC-γ1. COS7 cells expressing 
wild-type or Y509A/F510A mutant PLC-γ1 were labeled with myo-[2-3H] 
inositol (2 μCi/ml) for 24 h. Labeled cells were pretreated with 20 mM 
LiCl for 15 min, and further treated with EGF for 20 min, or left untreated. 
Extracts were loaded onto anion exchange columns. Half of the total in-
ositol phosphate eluted from the column was used for scintillation 
counting. Western blot images [anti-FLAG immunoblot (above) and an-
ti-β-actin immunoblot (below)] within a box represent the expression lev-
els of mutant proteins, thus including normalization. Data are presented 
as averages of triplicate determinations (means± SD), from either of 
the two experiments, which yielded similar results.
activation upon anti-IgM stimulation in a chicken 
B-cell line, P10-14. 
    Here, we show that the Y509A/F510A mutation 
in PLC-γ1 significantly enhances both Y783 
phosphorylation and IP3 generation, compared to 
the activity of the wild-type counterpart, upon EGF 
stimulation. Interestingly, a different substitution, 
Y783F, in the Y509A/F510A protein, generates a 
triple point PLC-γ1 (Y509A/F510A/Y783F) mutant, 
which is unable to phosphorylate tyrosine at 
position 783, but retains an increased capacity for 
inositol phosphate generation to a similar extent as 
wild-type PLC-γ1 active in EGF-treated COS7 
cells. Our results suggest that Y509A/F510A 
mutant no longer requires Y783 phosphorylation 
step for enzyme activation in vivo.
Results 
EGF promotes Y783 phosphorylation in the 
Y509A/F510A PLC-γ1 mutant
Previous studies by our group focusing on identi-
fication of the binding site in the split PH domain of 
PLC-γ1 revealed that Y509 and F510 were 
potential regulatory residues of enzyme activity, via 
mediation of protein-protein association (Chang et 
al., 2002). Unexpectedly, anti-phosphotyrosine 
immunoblotting experiments revealed an unusually 
high level of tyrosine phosphorylation in the 
Y509A/F510A PLC-γ1 mutant protein (Figure 1A). 
COS7 cells transfected with FLAG-tagged cDNA 
encoding either Y509A/F510A mutant or wild-type 
PLC-γ1 protein were treated with 50 ng/ml EGF for 
10 min, or untreated, and cell lysates were subjec-
ted to immunoprecipitation using anti-FLAG antibo-
dies. In an anti-phosphotyrosine (monoclonal anti-
body PY20) immunoblot, the tyrosine phospho-
rylation level of the mutant was almost five-fold 
higher than that of wild-type PLC-γ1, as shown by 
image intensity analysis (Figure 1A). 
    Next, we determined the tyrosine residue 
phosphorylated by the EGF-receptor tyrosine 
kinase. Resolved proteins, prepared as described 
above, were immunoblotted using anti-phosphoty-
rosine-specific antibodies for PLC-γ1. As shown in 
Figures 1B and 1D, anti-pY771 and anti-pY1254 
immunoblots did not reveal increased tyrosine 
phosphorylation in the Y509A/F510A mutant, whe-
reas Y783 phosphorylation was significantly increa-
sed in the double mutant, compared to wild-type 
PLC-γ1, following EGF treatment (Figure 1C). Our 
results indicate that the Y509A/F510A mutations 
strongly promoted Y783 phosphorylation upon 
EGF stimulation in vivo.
EGF promotes IP3 generation in the Y509A/F510A 
mutant PLC-γ1 
Next, we examined the PIP2-hydrolyzing activity of 
mutant PLC-γ1 in COS7 cells, in view of the finding 
that Y783 phosphorylation was a prerequisite for 
PLC-γ1 activation (Kim et al., 1991; Poulin et al., 
2005). For activity analysis, Y509A/F510A mutant 
and wild-type PLC-γ1 constructs were transfected 
into COS7 cells, and either treated with EGF for 20 
min, or left untreated. As illustrated in Figure 2, the 
activity of the Y509A/F510A mutant was twice that 
of wild-type PLC-γ1 in the presence of EGF. In 
terms of protein expression and IP3 production, 
activity was increased by half (Figure 2). Intere-
stingly, even in the absence of EGF, Y509A/F510A 
mutant PLC-γ1 displayed an enhanced IP3 gene-
ration capacity, relative to that of EGF-treated 
wild-type PLC-γ1 (Figure 2). Thus, it appeared that 
Y509A/F510A mutant PLC-γ1 was constitutively 
activated in COS7 cells. Our results collectively 
indicate that the Y509A/F510A mutant has a higher 
inositol phospholipid-hydrolyzing activity than does 
wild-type PLC-γ1, in vivo.
Y509A/Y510A mutant PLC-γ1 does not require Y783 
phosphorylation for activation
As the Y509A/F510A mutant displayed a remar-
kable increase in IP3 generation with respect to its 
wild-type counterpart, even without EGF stimul-
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Figure 3. Comparison of Y783 phosphorylation and IP3 production of Y509A/F510A and Y509A/F510A/Y783F mutant PLC-γ1 proteins. (A) Wild-type 
PLC-γ1 and the derivative mutant PLC-γ1, from COS7 cells transfected with pFLAG-PLC-γ1 (WT), -H335Q, -Y509A/F510A, and -Y509A/F510A/Y783F, 
were immunoprecipitated using anti-FLAG antibody, and resolved proteins were immunoblotted employing an anti-pY783 antibody. (B) COS7 cells ex-
pressing the above combinations of DNA were labeled with myo-[2-3H] inositol (2 μCi/ml) for 24 h. Labeled cells were treated with EGF for 20 min, or left 
untreated. Extracts were applied to an anion exchange column, and half the level of total inositol phosphate eluted from the column used for scintillation 
counting. Western blot images [anti-FLAG immunoblot (above) and anti-β-actin immunoblot (below)] represent expression levels of mutant proteins, in-
cluding normalization data. Data are presented as averages of triplicate determinations (means± SD) from one of two experiments, which yielded sim-
ilar results. 
ation, we addressed the role of Y783 phosphory-
lation in mutant PLC-γ1 activity. An additional 
Y783F mutation was introduced into Y509A/F510A 
PLC-γ1 and the inositol phospholipid-hydrolyzing 
activity of the triple mutant (Y509A/F510A/Y783F) 
was examined in vivo. Initially, we compared the 
phosphorylation status of 783 residue of Y509A/ 
F510A/Y783F with that of the Y509A/F510A 
mutant by anti-pY783 immunoblotting (Figure 3A). 
Recombinant constructs were transfected into 
COS7 cells and immunoprecipitated with an 
anti-FLAG antibody, followed by immunoblotting 
with an anti-pY783 antibody. H335Q, a lipase-inac-
tive mutant used as a catalytically inactive control, 
and wild-type PLC-γ1, displayed enhanced levels 
of Y783 phosphorylation upon EGF stimulation, 
whereas no immunoreactive band was observed 
for the Y509A/F510A/Y783F mutant when anti-pY783 
antibody was used as a probe. This suggests that 
tyrosine phosphorylation at position 783 was 
completely abolished in the Y509A/F510A/Y783F 
mutant (Figure 3A). However, as shown above 
(Figure 1C), Y783 phosphorylation was signifi-
cantly increased in the Y509A/F510A mutant upon 
EGF stimulation (Figure 3A). The Y783F PLC-γ1 
mutant was not phosphorylated at residue 783, as 
described elsewhere (data not shown).
    Subsequently, we compared the IP3-production 
abilities of the Y509A/F510A and Y509A/F510A/ 
Y783F mutant proteins. The Y509A/F510A/Y783F 
mutant generated lower levels of total inositol 
phosphate than did the Y509A/F510A mutant, but 
the levels were comparable to those created by 
wild-type PLC-γ1 protein action after EGF stimu-
lation, thus suggesting that Y783 phosphorylation 
was not critical for enzyme activity in the 
Y509A/F510A mutant (Figure 3B). Additionally, the 
Y509A/F510A mutant protein produced increased 
amounts of IP3 (approximately two-fold higher than 
that after action of wild-type PLC-γ1) in quiescent 
COS7 cells, whereas vector-transfected control 
and wild-type PLC-γ1-transfected cells produced 
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basal levels of IP3 in the absence of EGF 
stimulation (Figure 3B). Based on these results, we 
would propose that Y783 phosphorylation is 
important for wild-type PLC-γ1 activation, but is not 
a prerequisite for activation of the Y509A/F510A 
mutant protein. Moreover, Y509A/F510A PLC-γ1 
was constitutively active in vivo. Thus, the split half 
of the PH domain, located immediately upstream of 
the N-terminal SH2 of PLC-γ1, which contains 
Y509 and F510, may be key in elucidation of the 
PLC-γ1 activation mechanism. 
Discussion
Activated PLC-γ1 produces second messengers, 
including diacylglycerol and IP3, and is thus a key 
enzyme in cell signaling. PLC-γ1, a relatively large 
molecule consisting of 1,290 amino acids, is 
structurally arranged into two PH domains, two 
SH2 domains, one SH3 domain, and catalytic X 
and Y domains. Details of the mechanism under-
lying PLC-γ1 activation remain to be established. 
    To date, the preferred model suggested for the 
activation mechanism is Y783 phosphorylation that 
may result in conformational changes within the 
molecule (Poulin et al., 2005). Phosphorylated 
PLC-γ1 intramolecularly binds the C-terminal SH2 
domain, promoting higher accessibility to the 
substrate, PIP2 (DeBell et al., 1999, 2007; Poulin et 
al., 2005). Data of our present study show that the 
Y509A/F510A mutant protein exhibits a remar-
kable increase in PIP2-hydrolyzing activity, without 
a need for Y783 phosphorylation. H335Q PLC-γ1 
was previously identified as a lipase-inactive 
mutant (Smith et al., 1994; Huang et al., 1995). 
However, no in vivo lipase-active mutants have 
been reported to date. Thus, we generated a 
constitutively active mutant, PLC-γ1, which may be 
useful for clarification of the PLC-γ1 activation 
mechanism. 
    The Y509A/F510A mutant displayed a robust 
increase in Y783 phosphorylation, compared to 
wild-type PLC-γ1, following EGF treatment (Figure 
1C). The mutant protein additionally exhibited a 
higher IP3 production rate compared to that 
achieved by the wild-type counterpart (Figure 2). 
The Y783 phosphorylation level was proportional 
to IP3 production rate, consistent with what was 
noted with wild-type PLC-γ1, as reported previously 
(Meisenhelder et al., 1989; Kim et al., 1990, 1991; 
Wahl and Carpenter, 1998; Rhee, 2001; Sekiya et 
al., 2004; Poulin et al., 2005; Choi et al., 2006). 
However, the most interesting finding with respect 
to the enzyme activation mechanism is that the 
Y509A/F510 mutant produced higher levels of IP3 
than did wild-type protein, even in the absence of 
EGF stimulation (Figures 2 and 3B). Y783 
phosphorylation is generally considered to be 
necessary for PLC-γ1 activation. Our results show 
that the Y509A/F510A/Y783F mutant retained 
PIP2-hydrolyzing activity, to a similar extent as 
shown by wild-type protein, conclusively indicating 
that Y783 phosphorylation is unnecessary for 
Y509A/F510A PLC-γ1 activation, and supporting 
constitutive activation of the mutant protein in vivo 
(Figure 3B). 
    In terms of the PLC-γ1 activation mechanism, 
we propose that conformational changes occur in 
the split PH domain of the Y509A/F510A mutant. 
Both tyrosine and phenylalanine within the split PH 
domain are aromatic residues responsible for hydro-
phobic interactions. Thus, the overall structure in 
the region of the split PH domain may be disrupted 
by substitution of both amino acids with neutral 
residues, such as alanine. So the Y509A/F510A 
mutation of the split PH domain may result in 
increased substrate accessibility. In a previous 
study by our group, the Y509A/F510A mutant was 
shown to lose binding affinity for EF-1α, but 
retained an affinity for inositol phospholipid (Chang 
et al., 2002; Kim et al., 2004). Moreover, assay of 
the enzyme activity of the purified Y509A/F510A 
mutant protein, in sonicated micelles in vitro, 
revealed no change in PIP2 hydrolysis activity 
(Chang et al., 2002). In contrast, our current results 
show that the Y509A/F510A mutant protein 
produced elevated levels of IP3, both in the 
presence and absence of agonist in vivo. When it 
is considered that PIP2 hydrolysis by inactive 
PLC-γ1 is inhibited in quiescent cells by effective 
removal of substrate via intramolecular interaction 
(Poulin et al., 2005; DeBell et al., 2007), a possible 
explanation for the current finding is that the 
Y509A/F510A mutation results in an open-state 
conformation that retains activity with respect to 
substrate hydrolysis. This theory is supported by 
the existence of a PLC catalytic-inhibitory peptide 
(PCI peptide) encoded immediately downstream of 
the C-terminal SH2 domain of PLC-γ1 (Homma 
and Takenawa, 1992; Homma et al., 1997). For 
example, the Y509A/F510A mutation may induce a 
conformational change, leading to concealment of 
the PCI peptide within the molecule. 
    Following growth factor stimulation, inactive 
PLC-γ1 translocates from the cytosol to the mem-
brane where PLC-γ1 is activated to hydrolyze 
membrane-anchored inositol phospholipid (Falasca 
et al., 1998; Rhee, 2001). So it is acceptable that 
the Y509A/F510A/Y783F mutant PLC-γ1 shows an 
increased PIP2-hydrolyzing activity upon EGF 
treatment. Following EGF stimulation, active form 
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of the Y509A/F510A/Y783F mutant protein (already 
activated by mutations of both Y509 and F510 
residues) just translocates from the cytosol to the 
membrane to access PIP2. Whereas no direct 
evidence for structural delineation of Y509A/F510A 
activation is yet available, further experiments with 
our mutant protein may facilitate an understanding 
of the PLC-γ1 activation mechanism.
Methods
Antibodies and cell culture 
Monoclonal and polyclonal anti-PLC-γ1 antibodies were 
obtained from Sigma-Aldrich (St. Louis, MO). Polyclonal 
anti-phospho Tyr-771, Tyr-783 and Tyr-1254 antibodies 
have been described previously (Bae et al., 2002). The 
monoclonal anti-FLAG antibody and EGF were purchased 
from Sigma-Aldrich (St. Louis, MO). HRP-conjugated goat 
anti-mouse and goat anti-rabbit antibodies were acquired 
from Upstate Inc. (Lake Placid, NY). COS7 cells were 
cultured in DMEM containing 10% FBS and 100 U 
penicillin-streptomycin at 37oC. 
Vector constructs 
Rat cDNAs encoding wild-type PLC-γ1 (Suh et al., 1988), 
Y509A/F510A (Chang et al., 2002), and Y509A/F510A/ 
Y783F mutant proteins were inserted into the Xba I site of 
the pFLAG-CMV-2 vector (Sigma-Aldrich, St. Louis, MO) 
for expression in COS7 cells. All constructs were prepared 
using the Qiagen Plasmid Maxi Kit (Qiagen Inc., Santa 
Clarita, CA), and sequences were confirmed by DNA 
sequencing of the ligation and mutation sites. COS7 cells 
were transfected with Lipofectamine reagent (Gibco BRL, 
Gaithersburg, MD). At 48 h after transfection, cells were 
treated with 50 ng/ml EGF for 20 min or left untreated, and 
harvested for immunoprecipitation. 
Immunoblotting and immunoprecipitation
COS7 cells transfected with plasmids encoding FLAG-tag-
ged PLC-γ1 constructs were washed twice with PBS and 
lysed with radio immunoprecipitation assay (RIPA) buffer 
(20 mM HEPES, pH 7.2, 1% Triton X-100, 1% sodium 
deoxycholate, 0.1% SDS, 150 mM NaCl, 1 mM sodium 
orthovanadate, 10 μg/ml leupeptin, 10 μg/ml aprotinin and 
1 mM PMSF). For agonist stimulation, cells were 
serum-starved for 30 h, followed by treatment with 50 
ng/ml EGF for 10-20 min. Lysate supernatants were 
precleared by incubation with anti-FLAG M2 affinity gel 
(Sigma-Aldrich) for 30 min. Precleared cell lysates were 
incubated for 2 h with anti-FLAG antibodies conjugated 
with 50 μl of a 50% slurry of anti-FLAG M2 affinity gel. 
Immune complexes were collected by centrifugation, 
washed three times with ice-cold RIPA buffer, and resolved 
with 10% SDS-PAGE, followed by blotting on to a PVDF 
membrane. The blot was probed with anti-FLAG or 
anti-phospho-specific antibodies, and immunoreactive 
bands visualized by ECL detection using HRP-conjugated 
goat anti-mouse IgG.
Measurement of inositol phosphate generation in 
COS7 cells
COS7 cells expressing Y509A/F10A mutant or wild-type 
PLC-γ1 were seeded at a density of 5× 105 cells into 60 
mm dishes, and cultured for 2 days. Cells were labeled 
with myo-[2-3H] inositol (2 μCi/ml) in inositol-free DMEM for 
24 h. Subsequently, labeled cells were washed with PBS, 
and pretreated with 20 mM LiCl for 15 min in bicar-
bonate-free DMEM containing 20 mM HEPES (pH 7.2) and 
1 mg/ml of bovine serum albumin. Stimulation was initiated 
by addition of the indicated concentrations of EGF for 20 
min, and terminated with 500 μl of ice-cold 5% HClO4. 
After 30 min in an ice bath, extracts were centrifuged, 
diluted (1:5) with distilled water, and applied to a Bio-Rad 
Dowex AG1-X8 anion exchange column. The column was 
washed with 10 ml of distilled water, followed by 10 ml of 
0.06 M sodium tetraborate. Total inositol phosphates were 
eluted with a solution containing 1 M ammonium formate 
and 0.1% formic acid. Half of the eluted volume was 
subjected to scintillation counting for estimating the 
quantity of inositol phosphate.
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